Literature DB >> 24068833

Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death.

John S Lazo1, Elizabeth R Sharlow, Michael W Epperly, Ana Lira, Stephanie Leimgruber, Erin M Skoda, Peter Wipf, Joel S Greenberger.   

Abstract

Ionizing radiation (IR) induces genotoxic stress that triggers adaptive cellular responses, such as activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling cascade. Pluripotent cells are the most important population affected by IR because they are required for cellular replenishment. Despite the clear danger to large population centers, we still lack safe and effective therapies to abrogate the life-threatening effects of any accidental or intentional IR exposure. Therefore, we computationally analyzed the chemical structural similarity of previously published small molecules that, when given after IR, mitigate cell death and found a chemical cluster that was populated with PI3K inhibitors. Subsequently, we evaluated structurally diverse PI3K inhibitors. It is remarkable that 9 of 14 PI3K inhibitors mitigated γIR-induced death in pluripotent NCCIT cells as measured by caspase 3/7 activation. A single intraperitoneal dose of LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one], administered to mice at 4 or 24 hours, or PX-867 [(4S,4aR,5R,6aS,9aR,Z)-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,7,10-trioxo-1-(pyrrolidin-1-ylmethylene)-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-H]isochromen-5-yl acetate (CID24798773)], administered 4 hours after a lethal dose of γIR, statistically significantly (P < 0.02) enhanced in vivo survival. Because cell cycle checkpoints are important regulators of cell survival after IR, we examined cell cycle distribution in NCCIT cells after γIR and PI3K inhibitor treatment. LY294002 and PX-867 treatment of nonirradiated cells produced a marked decrease in S phase cells with a concomitant increase in the G1 population. In irradiated cells, LY294002 and PX-867 treatment also decreased S phase and increased the G1 and G2 populations. Treatment with LY294002 or PX-867 decreased γIR-induced DNA damage as measured by γH2AX, suggesting reduced DNA damage. These results indicate pharmacologic inhibition of PI3K after IR abrogated cell death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24068833      PMCID: PMC3836314          DOI: 10.1124/jpet.113.208421

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

Review 1.  Cell cycle checkpoint signaling through the ATM and ATR kinases.

Authors:  R T Abraham
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

2.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

3.  Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators.

Authors:  Jean-Claude M Rwigema; Barbara Beck; Wei Wang; Alexander Doemling; Michael W Epperly; Donna Shields; Julie P Goff; Darcy Franicola; Tracy Dixon; Marie-Céline Frantz; Peter Wipf; Yulia Tyurina; Valerian E Kagan; Hong Wang; Joel S Greenberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-13       Impact factor: 7.038

4.  Exposure to ionizing radiation causes long-term increase in serum estradiol and activation of PI3K-Akt signaling pathway in mouse mammary gland.

Authors:  Shubhankar Suman; Michael D Johnson; Albert J Fornace; Kamal Datta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-28       Impact factor: 7.038

5.  IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter.

Authors:  G C Mitchell; J L Fillinger; S Sittadjody; J L Avila; R Burd; K H Limesand
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

6.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

7.  Strategies for discovery of small molecule radiation protectors and radiation mitigators.

Authors:  Joel S Greenberger; David Clump; Valerian Kagan; Hülya Bayir; John S Lazo; Peter Wipf; Song Li; Xiang Gao; Michael W Epperly
Journal:  Front Oncol       Date:  2012-01-13       Impact factor: 6.244

Review 8.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

9.  Effects of multiple conformers per compound upon 3-D similarity search and bioassay data analysis.

Authors:  Sunghwan Kim; Evan E Bolton; Stephen H Bryant
Journal:  J Cheminform       Date:  2012-11-07       Impact factor: 5.514

10.  Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells.

Authors:  Elke Firat; Astrid Weyerbrock; Simone Gaedicke; Anca-Ligia Grosu; Gabriele Niedermann
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more
  6 in total

1.  Rh(iii)-catalyzed synthesis of dibenzo[b,d]pyran-6-ones from aryl ketone O-acetyl oximes and quinones via C-H activation and C-C bond cleavage.

Authors:  Wei Yang; Haonan Zhang; Yu Liu; Cuiman Tang; Xiaohui Xu; Jiaqi Liu
Journal:  RSC Adv       Date:  2022-05-12       Impact factor: 4.036

2.  A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis.

Authors:  Elizabeth R Sharlow; Stephanie Leimgruber; Ana Lira; Michael J McConnell; Andrés Norambuena; George S Bloom; Michael W Epperly; Joel S Greenberger; John S Lazo
Journal:  ACS Chem Biol       Date:  2016-03-14       Impact factor: 5.100

Review 3.  Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.

Authors:  Vijay K Singh; Patricia L P Romaine; Thomas M Seed
Journal:  Health Phys       Date:  2015-06       Impact factor: 1.316

Review 4.  Radiation countermeasure agents: an update (2011-2014).

Authors:  Vijay K Singh; Victoria L Newman; Patricia L P Romaine; Stephen Y Wise; Thomas M Seed
Journal:  Expert Opin Ther Pat       Date:  2014-10-14       Impact factor: 6.674

Review 5.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

Authors:  Jessica Lawrence; Richard Nho
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

6.  Exploring the differentially expressed genes in human lymphocytes upon response to ionizing radiation: a network biology approach.

Authors:  Tamizh Selvan Gnana Sekaran; Vishakh R Kedilaya; Suchetha N Kumari; Praveenkumar Shetty; Pavan Gollapalli
Journal:  Radiat Oncol J       Date:  2021-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.